Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

NCT03837977 | Completed Phase 2 DMC

• 1 other identifier: CFTSp116
• Study Type: interventional
• Target: 58
• Locations: 1 country
• Sites: 4

Brief Summary

There is currently no standard treatment beyond first-line etoposide/platinum-based chemotherapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. Therefore the treatment of patients whose disease progresses on or after this first-line treatment is an area of unmet need. Combination regimens such as irinotecan/5-fluorouracil/folinic acid are a second-line treatment option currently used in Europe and world-wide for this subset of patients. However, there is currently no trial evidence supporting this treatment regimen in these patients. Results of the NAPOLI-1 phase III trial of liposomal irinotecan in the treatment of patients with metastatic pancreatic adenocarcinoma after gemcitabine-based therapy reported improved survival for those patients who received a combination of liposomal irinotecan with 5-FU/folinic acid compared to those patients who received 5-FU/folinic acid alone. Liposomal irinotecan has been found to show an improved distribution into tumour tissue in comparison to irinotecan, and this may have clinical benefit in patients with extra-pulmonary neuroendocrine carcinoma. Docetaxel is standardly used as a second-line treatment option in patients with small cell lung cancer who have progressed on primary etoposide-platinum combination therapy. Therefore this drug could also have clinical benefit in patients with extra-pulmonary neuroendocrine carcinoma as the biology of the disease is similar to small cell lung cancer. The overall aim of the NET-02 trial is to select a treatment for continuation to a Phase III trial. The intention of the trial is to determine whether liposomal irinotecan/5-fluorouracil/folinic acid and docetaxel are sufficiently active in this population of patients. If both treatments are found to be efficacious, selection criteria will be applied to select a treatment to take forward. 102 eligible participants will be randomised to receive either liposomal irinotecan/5-fluorouracil/folinic acid given every 14 days, or docetaxel given every 21 days. Participants will be treated for a minimum of 6 months or until discontinuation of treatment as per protocol.

Conditions

Oncology; Neuroendocrine Carcinoma

Outcome Measures

Primary Outcomes (1)

• Progression-free survival defined as a binary outcome (progression-free or not)

  treatment start date until 6 months, assessed at 8 weekly intervals by CT scan

Secondary Outcomes (7)

• Progression-free survival defined as time from randomisation to progression or death from any cause.

  randomisation until 6 months after the last participant is randomised (end of trial), assessed at 8 weekly intervals by CT scan and death is continuously assessed

• Overall survival defined as time from randomisation to death from any cause.

  randomisation until 6 months after the last participant is randomised (end of trial), death is continuously assessed

• Objective response rate defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

  start of treatment until 6 months after the last participant is randomised (end of trial)

• Toxicity defined as the number of participants with treatment-related adverse events as assessed by common terminology criteria for adverse events (CTCAE) v5.0.

  treatment start date until 6 months after the last participant is randomised (end of trial), assessed at 2 (nal-IRI/5-FU/folinic acid) or 3 (docetaxel) weekly intervals

• Quality of life assessed according to the patient reported outcome measures; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30

  randomisation until 6 months after the last participant is randomised (end of trial), assessed at 6 weekly intervals

Study Arms (2)

nal-IRI, 5-FU and racemic folinic acid

ACTIVE COMPARATOR

liposomal Irinotecan (naI-IRI) (80mg/m\*2 intravenously over 90 minutes (± 10 minutes) prior to Fluorouracil (5-FU) 5-FU 2400 mg /m\*2 BSA infusor over 46 hours racemic folinic acid (as per local standard practice) every 14 days

Drug: Liposomal Irinotecan; Drug: Fluorouracil; Drug: Folinic Acid

docetaxel

ACTIVE COMPARATOR

75mg/m\*2 intravenously over 60 minutes) every 21 days\]

Drug: Docetaxel

Interventions

Liposomal Irinotecan DRUG

Arm I

Also known as: Onivyde

nal-IRI, 5-FU and racemic folinic acid

Fluorouracil DRUG

Arm I

nal-IRI, 5-FU and racemic folinic acid

Folinic Acid DRUG

Arm I

nal-IRI, 5-FU and racemic folinic acid

Docetaxel DRUG

Arm II

docetaxel

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years and life expectancy ≥3 months.
• Diagnosed with poorly differentiated (as defined by the World Health Organisation in 2010, Ki 67 ≥20%) extra-pulmonary neuroendocrine carcinoma (NEC grade 3, confirmed by histology). (Carcinoma of unknown primary is allowed if lung primary has been excluded following review by the multi-disciplinary team).
• Prior treatment with first-line platinum-based chemotherapy for NEC in the advanced setting and ≥28 days from Day 1 of the previous treatment cycle.
• Documented radiological evidence of disease progression OR discontinuation of first-line platinum-based chemotherapy due to intolerance.
• Measurable disease according to RECIST 1.1
• Eastern Co-operative Oncology Group (ECOG) performance status ≤2
• Adequate renal function with serum creatinine ≤1.5 times upper limit of normal (ULN) and creatinine clearance ≥50ml30ml/min according to Cockroft-Gault or Wright formula. If the calculated creatinine clearance is less than 30 ml/min, glomerular filtration rate (GFR) may be assessed using either Cr51-EDTA or 99mTc-DTPA clearance method to confirm if GFR is ≥30 ml/min).
• Adequate haematological function: Hb ≥90g/L, WBC ≥3.0 x 109/L, ANC ≥1.5 x 109/L, platelet count ≥100 x 109/L.
• Adequate liver function: serum total bilirubin 1.5 x ULN (biliary drainage is allowed for biliary obstruction) and ALT and/or AST 2.5 x ULN in the absence of liver metastases, or 5 x ULN in the presence of liver metastases.
• A negative pregnancy test is required at registration in women of childbearing potential.
• Men and women of reproductive potential must agree to use a highly effective form of contraception during the study and for 6 months following the last dose of trial treatment. In addition, male participants should use a condom during study participation and for 6 months following the last dose of trial treatment.
• Patients must be able to provide written informed consent.
• Patients must be able and willing to comply with the terms of the protocol.

You may not qualify if:

• Known or suspected allergy or hypersensitivity reaction to any of the components of study treatment or their excipients.
• Use (including self-medication) within one week of randomisation and for the duration of the study of any of the following: St. John's wort, grapefruit, Seville oranges, medicines known to inhibit UGT1A1 (e.g. atazanavir, gemfibrozil, indinavir) and medicines known to inhibit or induce either CYP3A4 or CYP3A5
• Previous treatment (for neuroendocrine carcinoma) with any of the components of combination chemotherapy regimens detailed in this study (nal-IRI or 5-FU or irinotecan or topoisomerase inhibitors or taxane-based therapy).
• Incomplete recovery from previous therapy in the opinion of the investigator (surgery/adjuvant therapy/radiotherapy/chemotherapy in advanced setting), including ongoing peripheral neuropathy of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 from previous platinum-based therapy.
• Concurrent palliative radiotherapy involving target lesions used for this study (\<28 days from discontinuation of radiotherapy). Radiotherapy for non-target lesions is allowed if other target lesions are available outside the involved field.
• Patients must not have a history of other malignant diseases (within the previous 3 years, and there must be no evidence of recurrence), other than:
• Extra-pulmonary neuroendocrine carcinoma.
• Non-melanoma skin cancer where treatment consisted of resection only or radiotherapy.
• Ductal carcinoma in situ (DCIS) where treatment consisted of resection only.
• Cervical carcinoma in situ where treatment consisted of resection only.
• Superficial bladder carcinoma where treatment consisted of resection only.
• Documented brain metastases, unless adequately treated (surgery or radiotherapy only), with no evidence of progression and neurologically stable off anticonvulsants and steroids.
• Clinically significant gastrointestinal disorder (in the opinion of the treating clinician) including hepatic disorders, bleeding, inflammation, obstruction, or diarrhoea ≥CTCAE grade 1 (at time of study entry).
• New York Heart Association (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure .
• Known active hepatitis B virus, hepatitis C virus or HIV infection.

Sponsors & Collaborators

• The Christie NHS Foundation Trust: lead
• University of Leeds: collaborator
• Servier: collaborator
• National Institute for Health Research, United Kingdom: collaborator

Study Sites (4)

The Beaston West of Scotland Cancer Center, NHS Greater Glasgow and Clyde

Glasgow, United Kingdom

Location

Hammersmith Hospital, Imperial College Healthcare NHS Trust

London, United Kingdom

Location

The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom

Location

Weston Park Hospital, Sheffield Teaching Hospitals, NHS Trust

Sheffield, United Kingdom

Location

Related Publications (2)

• McNamara MG, Swain J, Craig Z, Sharma R, Faluyi O, Wadsley J, Morgan C, Wall LR, Chau I, Reed N, Sarker D, Margetts J, Krell D, Cave J, Sothi S, Anthoney A, Bell C, Patel A, Oughton JB, Cairns DA, Mansoor W, Lamarca A, Hubner RA, Valle JW. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. EClinicalMedicine. 2023 Jun 2;60:102015. doi: 10.1016/j.eclinm.2023.102015. eCollection 2023 Jun.

  PMID: 37287870 DERIVED

• Craig Z, Swain J, Batman E, Wadsley J, Reed N, Faluyi O, Cave J, Sharma R, Chau I, Wall L, Lamarca A, Hubner R, Mansoor W, Sarker D, Meyer T, Cairns DA, Howard H, Valle JW, McNamara MG. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open. 2020 Feb 5;10(2):e034527. doi: 10.1136/bmjopen-2019-034527.

  PMID: 32029495 DERIVED

MeSH Terms

Conditions

Neoplasms; Carcinoma, Neuroendocrine

Interventions

irinotecan sucrosofate; Fluorouracil; Leucovorin; Docetaxel

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Uracil; Pyrimidinones; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Formyltetrahydrofolates; Tetrahydrofolates; Folic Acid; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Coenzymes; Enzymes and Coenzymes; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Officials

• Mairead McNamara

  The Christie NHS Foundation Trust, The University of Manchester

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: The study is a randomised controlled trial. One hundred and two eligible participants will be randomised (1:1)

Study Record Dates

• First Submitted: September 27, 2018
• First Posted: February 12, 2019
• Study Start: November 13, 2018
• Primary Completion: November 26, 2024
• Study Completion: November 26, 2024
• Last Updated: December 30, 2024

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will share
• Time Frame: Data will be made available at the end of the trial, i.e. usually when all primary and secondary endpoints have been met and all key analyses are complete. Data will remain available from then on for as long as CTRU retains the data.
• Access Criteria: CTRU makes data available by a 'controlled access' approach. Data will only be released for legitimate secondary research purposes, where the Chief Investigator, Sponsor and CTRU agree that the proposed use has scientific value and will be carried out to a high standard (in terms of scientific rigour and information governance and security), and that there are resources available to satisfy the request. Data will only be released in line with participants' consent, all applicable laws relating to data protection and confidentiality, and any contractual obligations to which the CTRU is subject. The conditions of release for aggregate data may differ from those applying to individual participant data. Requests for aggregate data should also be sent to the above email address to discuss and agree suitable requirements for release.

Locations

GB (4)